Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial
Ezgi B Ulas, Nora D Purcell, Ilias Houda, Sayed M S Hashemi, Joris Veltman, Johannes M A Daniels, Marieke F Fransen, Teodora Radonic, Linda R Beeloo, Peter S N van Rossum, Febe van Maldegem, Nicole Barlo, Maria Disselhorst, Marjolein van Laren, Marian A Tiemessen, Svitlana Tarasevych, Jan M van Haarst, Peter van Tilburg, Peter W A Kunst, Arifa Moons-Pasic, Daniela E Oprea-Lager, Lilian J Meijboom, Natalja Bouwhuis, Tanja D de Gruijl, Suresh Senan, Famke L Schneiders, Idris Bahce · 2026
Read Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial by Ezgi B Ulas, Nora D Purcell, Ilias Houda, Sayed M S Hashemi, Joris Veltman, Johannes M A Daniels, Marieke F Fransen, Teodora Radonic, Linda R Beeloo, Peter S N van Rossum, Febe van Maldegem, Nicole Barlo, Maria Disselhorst, Marjolein van Laren, Marian A Tiemessen, Svitlana Tarasevych, Jan M van Haarst, Peter van Tilburg, Peter W A Kunst, Arifa Moons-Pasic, Daniela E Oprea-Lager, Lilian J Meijboom, Natalja Bouwhuis, Tanja D de Gruijl, Suresh Senan, Famke L Schneiders, Idris Bahce (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289357.txt.
Description
Ezgi B Ulas and colleagues describe a 2026 phase II trial plan, called RECLAIM, for metastatic lung cancer that stopped responding to anti-PD-1 therapy. Tumors with low or no PD-L1 often gain little from such therapy, and later options work poorly. The trial tests whether radiation plus two immune drugs can rescue response in this group.
The single-arm study aims for 30 evaluable patients whose tumors show low or negative PD-L1 and grew after first-line anti-PD-1 care. Treatment pairs ipilimumab and nivolumab with focused radiation to one to four lesions, then continues the drug pair. Main checks are safety plus disease control and shrinkage in lesions that got no radiation, at six and twelve weeks. Shrinkage away from radiated spots would signal a body-wide immune lift.
Catalog record
| CREATOR | Ezgi B Ulas, Nora D Purcell, Ilias Houda, Sayed M S Hashemi, Joris Veltman, Johannes M A Daniels, Marieke F Fransen, Teodora Radonic, Linda R Beeloo, Peter S N van Rossum, Febe van Maldegem, Nicole Barlo, Maria Disselhorst, Marjolein van Laren, Marian A Tiemessen, Svitlana Tarasevych, Jan M van Haarst, Peter van Tilburg, Peter W A Kunst, Arifa Moons-Pasic, Daniela E Oprea-Lager, Lilian J Meijboom, Natalja Bouwhuis, Tanja D de Gruijl, Suresh Senan, Famke L Schneiders, Idris Bahce |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42322 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |